| Literature DB >> 33390169 |
Ajaz A Bhat1, Sabah Nisar1, Selma Maacha2, Tatiana Correa Carneiro-Lobo3, Sabah Akhtar4, Kodappully Sivaraman Siveen4, Nissar A Wani5, Arshi Rizwan6, Puneet Bagga7, Mayank Singh8, Ravinder Reddy9, Shahab Uddin4, Jean-Charles Grivel2, Gyan Chand10, Michael P Frenneaux11, Mushtaq A Siddiqi12, Davide Bedognetti3,13,14, Wael El-Rifai15, Muzafar A Macha16, Mohammad Haris17,18.
Abstract
Esophageal cancer (EC) is a disease often marked by aggressive growth and poor prognosis. Lack of targeted therapies, resistance to chemoradiation therapy, and distant metastases among patients with advanced disease account for the high mortality rate. The tumor microenvironment (TME) contains several cell types, including fibroblasts, immune cells, adipocytes, stromal proteins, and growth factors, which play a significant role in supporting the growth and aggressive behavior of cancer cells. The complex and dynamic interactions of the secreted cytokines, chemokines, growth factors, and their receptors mediate chronic inflammation and immunosuppressive TME favoring tumor progression, metastasis, and decreased response to therapy. The molecular changes in the TME are used as biological markers for diagnosis, prognosis, and response to treatment in patients. This review highlighted the novel insights into the understanding and functional impact of deregulated cytokines and chemokines in imparting aggressive EC, stressing the nature and therapeutic consequences of the cytokine-chemokine network. We also discuss cytokine-chemokine oncogenic potential by contributing to the Epithelial-Mesenchymal Transition (EMT), angiogenesis, immunosuppression, metastatic niche, and therapeutic resistance development. In addition, it discusses the wide range of changes and intracellular signaling pathways that occur in the TME. Overall, this is a relatively unexplored field that could provide crucial insights into tumor immunology and encourage the effective application of modulatory cytokine-chemokine therapy to EC.Entities:
Keywords: Chemokines; Cytokines; Drug targets; Epithelial-Mesenchymal transition; Esophageal cancer; Immune evasion; Inflammation; Tumor microenvironment
Year: 2021 PMID: 33390169 DOI: 10.1186/s12943-020-01294-3
Source DB: PubMed Journal: Mol Cancer ISSN: 1476-4598 Impact factor: 27.401